Thomas Jefferson University/Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania 19107
11 studies enrolling now · 35 studies all time
What they study most
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Advanced Lymphoma, Advanced Melanoma, Advanced Solid Tumor, Advanced Solid Tumors, Anal Squamous Cell Carcinoma, B-cell Non-Hodgkin Lymphoma, Bladder Cancer, Breast Cancer
Studies at this site
- LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas — Recruiting now
- A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations — Recruiting now
- Gene Therapy for HER-Positive Cancer (SENTRY-HER2) — Recruiting now
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer — Recruiting now
- FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors — Recruiting now
- SNV4818 in Participants With Advanced Solid Tumors — Recruiting now
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation — Recruiting now
- FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors — Recruiting now
- A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases — Recruiting now
- A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations — Running, not enrolling
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Running, not enrolling
- Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
- A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) — Starting soon
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide — Running, not enrolling
- Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies — Running, not enrolling
- Study to Evaluate CCS1477 in Advanced Tumours — Completed
- A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma — Stopped early
- Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors — Completed
- A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors — Completed
- A Drug-drug Interaction Study of Avapritinib and Midazolam — Completed
- A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) — Stopped early
- Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer — Completed
- A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors — Completed
- A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors — Stopped early
- ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma — Status unconfirmed
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies — Stopped early
- Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma — Stopped early
- A Study of PRT2527 in Participants With Advanced Solid Tumors — Completed
- Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma — Stopped early
- Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) — Completed
- A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas — Completed
- A Study of PRT1419 in Patients With Advanced Solid Tumors — Completed
- Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors — Stopped early
- Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer — Completed